The Panel has confirmed that Glucotrack has regained compliance with Nasdaq's stockholders' equity requirement. The decision represents an important milestone in the Company's efforts to strengthen its foundation and position for future growth.

"This is an important milestone, but more significantly, it is an acknowledgment of the substantial progress we have made in repositioning Glucotrack for the future," said Erik Emerson, Chief Executive Officer of Glucotrack. "Over the past several months, we have taken decisive actions to strengthen the Company, improve our financial foundation, and create a clearer path for long-term growth. We remain focused on executing our strategy, advancing our business objectives, and pursuing opportunities to create long-term shareholder value. We are approaching the months ahead with confidence, urgency, and a clear sense of purpose."

Management remains focused on disciplined execution as it advances its strategic priorities and works toward full compliance with all applicable Nasdaq standards.